Firms

Claris Ventures

Turin, Italy

Claris Ventures is an Italian venture capital manager that invests in and creates biotechnology companies developing new medicines. From Turin, it supports businesses from company formation and preclinical research through early clinical development, combining scientific assessment, financing, governance and operating support. Its portfolio spans neurology, oncology, metabolic disease, respiratory disease and other therapeutic areas; neuroscience investments include IAMA Therapeutics’ work on neuronal chloride regulation and serious central nervous system disorders. The legal manager is Claris Ventures SGR S.p.A., VAT 12116290011.

Founded: 2019
Type: Venture capital

Funds2

Claris Biotech Lombardia – Parallel Fund2026-07-172026-07-17€10M
Dedicated Claris Ventures parallel biotechnology fund under Lombardia Venture STEP, investing alongside Claris Biotech I and II in innovative life-sciences companies in Lombardy, especially new medicines and therapeutic technologies.
Claris Biotech II2025-04-232025-04-23—
Second Claris Ventures early-stage therapeutics venture fund, backing biotech startups and company creation emerging from scientific research, especially the Italian ecosystem, and advancing programs toward early clinical validation. Therapeutic areas include neurology and other diseases.

Team

Operations and support

Araceli AlbanoInternal Accounting & Administration

Ciro SpedaliereManaging Partner

Cristina TumiattiIndependent Director

Gianmarco PallaviciniSenior Associate

Giuditta MagnificoAssociate

Giulia VestriPartner

Laura Iris FerroSenior Advisor

Luca MelindoSenior Advisor

Manilo MaroccoSenior Advisor

Michael HodgesEntrepreneur in Residence

Paolo VigoInvestment Manager

Pietro PuglisiManaging Partner

Raffaele TroyaFinance & Administration Manager

Roberto De PontiSenior Advisor

Co-investing

3B Future Health Fund

Sibylla Biotech€23M · 2022-10-04

CDP Venture Capital SGR

Sibylla Biotech€23M · 2022-10-04

Indaco Venture Partners SGR

Sibylla Biotech€23M · 2022-10-04

Seroba Life Sciences

Sibylla Biotech€23M · 2022-10-04

V-Bio Ventures

Sibylla Biotech€23M · 2022-10-04

Investments

€23M2022-10-04

Sibylla Biotech

V-Bio Ventures, Claris Ventures, Indaco Venture Partners SGR, Seroba Life Sciences, Vi Partners, 3B Future Health Fund, CDP Venture Capital SGR, Vertis SGR

team@apexlogos.ai8 hours ago
Own current published roster has eight investment/finance staff and six advisers, entrepreneur-in-residence or independent-director relationships. Michael Hodges is currently Entrepreneur in Residence; February 2023 Partner appointment is historical and not applied as a current title. Own about page verifies founding in 2019 by Pietro Puglisi and Ciro Spedaliere. Biotech I is historical: own funds page splits EUR75m flagship and EUR10m parallel managed by CDP Venture Capital; aggregate EUR85m elsewhere is not assigned separately to both. Main fund II EUR100m remains target, not closed capital. Own EUR190m platform AUM headline is not a fund closing. Own profile and complete published relationships: https://www.clarisventures.com/ ; https://www.clarisventures.com/about/ ; https://www.clarisventures.com/team/ ; https://www.clarisventures.com/funds/.